We found that IL-28B gene delivery significantly decreased H22 hepatocellular carcinoma growth and reduced the frequency of splenic CD4+Foxp3+ T cells, which is consistent with a previous report described by Morrow et al. [10]. This evidence concerns the gene CD4 and hepatocellular carcinoma.